

**GLOBAL BIO-CHEM CONSOLIDATED REVENUE AMOUNTED TO APPROX
HK\$2.3 BILLION IN 2025
FACILITY CAPACITY ENHANCED ORDERLY TO MAINTAIN STEADY
BUSINESS GROWTH**

27 March 2026 – Global Bio-chem Technology Group Company Limited (“Global Bio-chem” or the “Company”, stock code: 00809, together with its subsidiaries, the “Group”) announced its audited financial results for the year ended 31 December 2025 (the “Year”). As Chinese lysine products have been imposed definitive anti-dumping duties starting from the second half of 2025, the local suppliers tend to sell their amino acids products to the domestic market, resulting in oversupply in the domestic market. The supply-demand imbalance led to a plunge in amino acids prices. The Group recorded mild increases on its consolidated revenue and gross profit of approximately HK\$2,278.5 million (2024: HK\$2,001.0 million) and approximately HK\$196.4 million (2024: HK\$191.0 million) for the Year respectively. Due to an increase in raw materials costs and a decline in lysine products prices, the Group’s gross profit margin was 8.6% (2024: 9.5%).

To cope with fierce domestic market competition, the Group moderately adjusted the production capacity of production facilities in amino acids business during the Year, and recorded a 36.6% year-on-year growth in sales volume to approximately 522,000 metric tonnes (“MT”) (2024: 382,000 MT). Among which, the Group’s sale volume of other corn refined products increased by approximately 42.2% with a revenue of approximately HK\$335.0 million (2024: HK\$264.2 million); the sales volume of the amino acids segment recorded an increase of approximately 34.6% with an approximately 11.9% year-on-year rise in revenue to approximately HK\$1,943.5 million (2024: HK\$1,736.9 million). However, affected by the anti-dumping policies, the Group’s average selling prices of other corn refined products and amino acids products dropped at a faster rate than that of the average production costs. The Group’s gross loss margin of other corn refined products was approximately 1.3% (2024: gross profit margin: 1.0%) with a gross loss of approximately HK\$4.5 million (2024: gross profit: HK\$2.6 million) for the Year; gross profit margin of the amino acids segment was approximately 10.3% (2024: 10.8%) with a gross profit of approximately HK\$200.9 million (2024: HK\$188.4 million).

Despite the decrease of the Group’s gross profit margin for the Year and the absence of a one-off gain of approximately HK\$1,962.1 million on disposal of subsidiaries for the corresponding prior year, the Group’s net profit amounted to approximately HK\$156.3 million (2024: HK\$769.6 million) for the Year. These were mainly attributable to the suppliers debt restructuring arrangement involving debt-to-equity-swap implemented in

October 2025 under the consensus with over 130 suppliers on the settlement of overdue payables valued at approximately RMB461.1 million, together with the settlement arrangements for the remaining rudder loans reached with, among others, Changchun Rudder Investment Group Co., Ltd. and the Changchun Municipal Government, in which the Group recorded one-off gains of approximately HK\$231.4 million and HK\$511.2 million respectively, and substantial reduction in its administrative expenses and other expenses.

In addition to the positive effects on the Group's financial position made by the suppliers debt restructuring arrangement and the settlement arrangements on the remaining rudder loans, the Group's controlling shareholder fully exercised the conversion rights under the convertible bonds during the Year, as such, the Group's net liabilities significantly narrowed down to approximately HK\$518.5 million (2024: HK\$1,954.4 million).

Furthermore, the Group has commenced the boiler refurbishment project in Changchun Dahe during the Year, which is expected to be completed in August 2026. With the use of ultra-high-temperature/ultra-high-pressure boilers, the Group will reduce the production costs of amino acids products and further enhance its market competitiveness.

Looking forward, the Group will continue to closely monitor market conditions, prudently promote capacity expansion, and strive to achieve steady growth in a challenging environment. The Group will also collaborate with various industry participants, universities and biochemical companies to further extend to product lines and facilitate full production resumption of the Xinglongshan site. The Group will utilise the pilot testing platform at the Xinglongshan site as an incubation stage for diversified and high-value-added products in the future, laying a solid foundation for its sustainable development.

About Global Bio-chem

Global Bio-chem (stock code: 00809.HK) has been listed on the Main Board of The Stock Exchange of Hong Kong Limited since 2001. The Group is principally engaged in the manufacture and sale, research and development of corn-based biochemical products in the People's Republic of China (the "PRC"). The Company's production facilities are based in Jilin province in the PRC.

- End -

Issued by: Global Bio-chem Technology Group Company Limited
 Through: CorporateLink Limited

Media Enquiry: CorporateLink Limited
 Shiu Ka Yue Tel: 2801 6198/ 9029 1865 Email: sky@corporatelink.com.hk
 Zoe Mak Tel: 2801 6090/ 6539 3300 Email: zoe@corporatelink.com.hk
 Zilia Zheng Tel: 2801 7393/ 5481 9812 Email: zilia@corporatelink.com.hk

Global Bio-chem's financial highlights

	For the year ended 31 December		
	2025	2024	Change %
Revenue (HK\$ million)	2,278.5	2,001.10	13.9
Gross profit (HK\$ million)	196.4	191.0	2.8
Profit for the Year (HK\$ million)	156.3	769.6	(79.7)
Earnings per share (HK cents)			
Basic	1.4	8.6	(83.7)
Diluted	0.6	2.9	(79.3)
Proposed final dividend per share (HK cents)	-	-	N/A